BIO-Europe 2025: Spain based ARTHEx Biotech is a European player in the DM1 space, and believes its microRNA strategy offers a dual benefit that it says is unique to the field

Nov 4, 2025
1 min read

CEO Frédéric Legros walks us through the science and explains why he believes ARTHEx has a unique approach compared to others we have seen in the field. The company raised an $87M series B in September.

https://vimeo.com/1133565079

Coverage brought to you by

Recent Posts

See All

$BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that$

BIO 2026: The gout market is currently served by two extremes, generic allopurinol in first line and a therapy for extreme refractory cases. Crystalys' experienced team wants to change that

BIO 2026: Rakuten Medical's drug-device 'photoimmunotherapy' is already approved in Japan for head & neck cancer - it is currently in a global phase 3 with an eye on a U.S. approval

BIO 2026: After presenting updated data at both ASH and EHA, Paris based Enterome is hoping to start a phase 3 for its multi-target peptide immunotherapy in follicular lymphoma

BIO-Europe 2025: Spain based ARTHEx Biotech is a European player in the DM1 space, and believes its microRNA strategy offers a dual benefit that it says is unique to the field

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight